Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ConfometRx

- PMLiVE

UCB’s antiepileptic drug gains new US indication

FDA approves Briviact as a monotherapy to treat POS

- PMLiVE

UCB collaborates with UK’s Medical Research Council

The partners will support researchers developing antibody-based therapeutics

- PMLiVE

FDA rejects Amgen’s osteoporosis hope romosozumab

Its partner UCB plans to submit the medicine for European approval later this year

- PMLiVE

UCB adds website for its Facebook-based Parkinson’s community

Says the site forms the next chapter for More than Motion

- PMLiVE

UCB launches UK product helpline for patients and HCPs

UCBCares will answer treatment queries and use feedback to drive innovation

- PMLiVE

Medical Research Council launches disease compounds research library

Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

- PMLiVE

UCB joins with Atlético Madrid for epilepsy awareness campaign

Spanish football players release video in support of ongoing initiative

Boehringer Ingelheim headquarters

Boehringer crowdsources psychiatric research team

Collaboration with BioMed X aims to identify new treatment approaches

Biogen Idec building

Biogen plans spin-out of haemophilia business

Aims to create two 'agile' specialist firms

- PMLiVE

Amgen and UCB’s romosozumab hits goals in male osteoporosis

Firms will discuss data with regulators before planning a new male licence application

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links